One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.1
Bottom line from this bounded source set
The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.1
Reviewed study record
Two early randomized trials
Design
Single- and multiple-ascending-exposure trials were randomized, blinded and placebo controlled; one part followed participants for 16 weeks.1
Population
Earlier parts enrolled normal-weight or overweight adults; the later multiple-exposure part enrolled adults with overweight or obesity. The abstract does not give total enrollment.1
Outcomes reported
The report described weight reductions and no serious or severe treatment-emergent adverse events. One participant discontinued because of gastrointestinal events.1
Limitations
The trials primarily assess early safety and pharmacology. Their size, follow-up and lack of an active comparator do not establish comparative tolerability or exclude uncommon harms.1
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.70753. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗